Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in ...
A phase I/II study of C019199 in combination with sintilimab in advanced malignancy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results